<DOC>
	<DOCNO>NCT00611962</DOCNO>
	<brief_summary>To evaluate efficacy oxaliplatin-paclitaxel combination i.e . evaluation tumor response rate use World Health Organization/Union Internationale Contre le Cancer ( WHO/UICC ) Indianapolis tumor marker ( human chorionic gonadotropin [ hCG ] , alpha fetoprotein [ AFP ] ) criteria metastatic germ cell cancer patient</brief_summary>
	<brief_title>Phase II Study Oxaliplatine-Paclitaxel Patients With Metastatic Germ Cell Tumor Refractory Cisplatin</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically proven germ cell cancer : gonadal ( include ovarian ) extragonadal , seminomatous non seminomatous , clinical presentation GCT elevate AFP level and/or hCG level ( &gt; =to 100 x ULN ) biopsy available Metastatic GCT patient : Progression disease define &gt; 10 % increase hCG and/or AFP marker ( and/or document progressive disease [ PD ] ) platinumbased chemotherapy le 6 month last cycle ( case grow non seminomatous tumor , without increase marker , histological documentation malignant tumor require , exclude grow mature teratoma ) At least 1 prior line chemotherapy contain CDDP + etoposide ; ( prior regimen high dose chemotherapy hematopoietic stem cell support permit ) Eastern Cooperative Oncology Group PS ( ECOG PS ) grade &lt; =to 2 At least 1 bidimensionally measurable lesion imaging ( CT scan ) &gt; =to 20 mm outside irradiated area OR significantly increase tumor marker &gt; 2 x ULN ( &gt; =to 2 consecutive test , even absence measurable lesion ) Age &gt; =to 18 Adequate bone marrow reserve Neutrophil count &gt; =to 1500/mm3 Platelets &gt; =to 100,000/mm3 Renal function : Creatinine &lt; 3 x ULN Liver function : Transaminases &lt; =to 2.5 x ULN , total bilirubin &lt; 1.5 x ULN ( liver metastasis , transaminase &lt; =to 5 x ULN ) Laboratory value obtain week precede study entry Neurosensory &lt; =to grade 1 NCI CTC Signed informed consent obtain prior study procedure Concomitant highdose steroid ( except antiemetic prophylaxis ) Pregnancy , breastfeed absence contraception sexually active patient Prior treatment oxaliplatin taxanes History second malignancy , except cure non melanoma skin cancer excise situ cervical carcinoma Symptomatic cerebral and/or leptomeningeal metastasis ( irradiated brain metastasis require corticosteroid treatment allow ) Treatment another experimental drug anticancer agent participation another clinical study within 30 day prior study Other serious illness uncontrolled infection Psychological , social geographical situation prevent regular followup Primary tumor brain/central nervous system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>